EGFR and neoplasm: Comparable to the two-in-one antibody HCP-LCE, it exhibits specific cellular binding to EGFR and PD-L1 double positive tumor cells, blocks the PD-1/PD-L1 axis and mediates a potent ADCC effect as an NKCE.